Updated
Reviewed
Jun. 03, 2021
Appendix B: Drug Characteristics Tables
Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
The older nucleoside reverse transcriptase inhibitors (NRTIs) didanosine (ddI), stavudine (d4T), and zidovudine (ZDV) are no longer used commonly in clinical practice and have been removed from this table. Please refer to the Food and Drug Administration product labels for ddI, d4T, and ZDV for information regarding these drugs.
| Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
Appendix B: Drug Characteristics Tables
Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
The older nucleoside reverse transcriptase inhibitors (NRTIs) didanosine (ddI), stavudine (d4T), and zidovudine (ZDV) are no longer used commonly in clinical practice and have been removed from this table. Please refer to the Food and Drug Administration product labels for ddI, d4T, and ZDV for information regarding these drugs.
| Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
Download Guidelines
- Section OnlyPDF (305.28 KB)
- Full GuidelinePDF (5.07 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)